News

A three-year study by Metropolis Healthcare reveals that 28.4 per cent of nearly 20,000 children screened for ...
Editas Medicine reports successful gene editing levels in stem cells, supporting potential treatment for sickle cell disease and beta thalassemia. Editas Medicine announced promising new data on ...
A new study reveals that over one in four Indian children under 12 carry inherited blood disorders. The findings highlight ...
Shares of CRISPR Therapeutics have lost momentum in recent years. Despite making significant clinical progress, CRISPR ...
In medical breakthrough, a baby diagnosed with rare genetic disorder is thriving after customized CRISPR gene editing therapy ...
Beta Thalassemia and sickle cell disorders continue to be major health challenges in India, with Thalassemia being one of the most common inherited blood disorders. The condition results in a ...
With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...
G ene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging.
Further, Editas Medicine has decreased expenses and costs thanks to discontinuing the development of reni-cel and laying off ...
KJ Muldoon came into the world with a genetic time bomb ticking inside him.
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy ...